Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer.

McDonald AM, Galgano SJ, McConathy JE, Yang ES, Dobelbower MC, Jacob R, Rais-Bahrami S, Nix JW, Popple RA, Fiveash JB.

Adv Radiat Oncol. 2019 Jun 19;4(4):649-658. doi: 10.1016/j.adro.2019.05.008. eCollection 2019 Oct-Dec.

2.

A Tris(3-pyridyl)stannane as a Building Block for Heterobimetallic Coordination Polymers and Supramolecular Cages.

Yang ES, Plajer AJ, García-Romero Á, Bond AD, Ronson TK, Álvarez CM, García-Rodríguez R, Colebatch AL, Wright DS.

Chemistry. 2019 Nov 4;25(61):14003-14009. doi: 10.1002/chem.201903498. Epub 2019 Oct 9.

PMID:
31469199
3.

Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics.

Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Frugé AD, Oster RA, Grizzle WE, Norian LA, Yang ES, Della Manna D, Jones LW, Azrad M, Krontiras H.

Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32637. [Epub ahead of print]

PMID:
31442303
4.

Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.

Willey CD, Anderson JC, Trummell HQ, Naji F, de Wijn R, Yang ES, Bredel M, Thudi NK, Bonner JA.

Biochem Biophys Res Commun. 2019 Sep 10;517(1):36-42. doi: 10.1016/j.bbrc.2019.06.159. Epub 2019 Jul 13.

PMID:
31311651
5.

The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.

Lin VTG, Yang ES.

J Natl Cancer Inst. 2019 Oct 1;111(10):1016-1022. doi: 10.1093/jnci/djz114.

PMID:
31165154
6.

Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans.

Jamshed H, Beyl RA, Della Manna DL, Yang ES, Ravussin E, Peterson CM.

Nutrients. 2019 May 30;11(6). pii: E1234. doi: 10.3390/nu11061234.

7.

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.

Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ.

EBioMedicine. 2019 Jun;44:419-430. doi: 10.1016/j.ebiom.2019.05.035. Epub 2019 May 22.

8.

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.

Ko SY, Akahata W, Yang ES, Kong WP, Burke CW, Honnold SP, Nichols DK, Huang YS, Schieber GL, Carlton K, DaSilva L, Traina-Dorge V, Vanlandingham DL, Tsybovsky Y, Stephens T, Baxa U, Higgs S, Roy CJ, Glass PJ, Mascola JR, Nabel GJ, Rao SS.

Sci Transl Med. 2019 May 15;11(492). pii: eaav3113. doi: 10.1126/scitranslmed.aav3113.

PMID:
31092692
9.

Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Jun;20(6):765. doi: 10.1038/s41590-019-0395-0.

PMID:
30980067
10.

WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure.

Seifert ME, Gaut JP, Guo B, Jain S, Malone AF, Geraghty F, Della Manna DL, Yang ES, Yi N, Brennan DC, Mannon RB.

Am J Transplant. 2019 Oct;19(10):2833-2845. doi: 10.1111/ajt.15372. Epub 2019 May 10.

PMID:
30916889
11.

Targeting DNA repair in precision medicine.

Beggs R, Yang ES.

Adv Protein Chem Struct Biol. 2019;115:135-155. doi: 10.1016/bs.apcsb.2018.10.005. Epub 2018 Dec 5.

PMID:
30798930
12.

Improvement of antibody functionality by structure-guided paratope engraftment.

Liu Q, Lai YT, Zhang P, Louder MK, Pegu A, Rawi R, Asokan M, Chen X, Shen CH, Chuang GY, Yang ES, Miao H, Wang Y, Fauci AS, Kwong PD, Mascola JR, Lusso P.

Nat Commun. 2019 Feb 13;10(1):721. doi: 10.1038/s41467-019-08658-4.

13.

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11. Erratum in: Nat Immunol. 2019 Apr 12;:.

14.

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.

McDonald AM, Dobelbower MC, Yang ES, Clark GM, Jacob R, Kim RY, Cardan RA, Popple R, Nix JW, Rais-Bahrami S, Fiveash JB.

Adv Radiat Oncol. 2018 Sep 19;4(1):90-95. doi: 10.1016/j.adro.2018.09.007. eCollection 2019 Jan-Mar.

15.

Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical Center.

Galgano SJ, Calderone CE, McDonald AM, Nix JW, deShazo M, Yang ES, McConathy JE, Rais-Bahrami S.

J Am Coll Radiol. 2019 Mar;16(3):315-320. doi: 10.1016/j.jacr.2018.09.026. Epub 2018 Nov 14. No abstract available.

PMID:
30447932
16.

The antitumor effects of entinostat in ovarian cancer require adaptive immunity.

Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC.

Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761. Epub 2018 Nov 13.

PMID:
30423192
17.

Best serum biomarker combination for ovarian cancer classification.

Song HJ, Yang ES, Kim JD, Park CY, Kyung MS, Kim YS.

Biomed Eng Online. 2018 Nov 6;17(Suppl 2):152. doi: 10.1186/s12938-018-0581-6.

18.

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.

Lin VTG, Nabell LM, Spencer SA, Carroll WR, Harada S, Yang ES.

J Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.

19.

Adoption and Utilization of an Emergency Department Naloxone Distribution and Peer Recovery Coach Consultation Program.

Samuels EA, Baird J, Yang ES, Mello MJ.

Acad Emerg Med. 2019 Feb;26(2):160-173. doi: 10.1111/acem.13545. Epub 2018 Oct 3.

PMID:
30074673
20.

Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples.

Coker MA, Dulaney C, McDonald A, Nix JW, Gordetsky JB, Yang ES, Dobelbower MC, Rais-Bahrami S.

Cureus. 2018 Apr 24;10(4):e2524. doi: 10.7759/cureus.2524.

21.

A Systematic Review of Longitudinal Cohort Studies Examining Unintentional Injury in Young Children.

Zonfrillo MR, Linakis JG, Yang ES, Mello MJ.

Glob Pediatr Health. 2018 May 9;5:2333794X18774219. doi: 10.1177/2333794X18774219. eCollection 2018.

22.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

23.

Reply to "Phase II prospective randomized trial of weight loss prior to radical prostatectomy".

Demark-Wahnefried W, Rais-Bahrami S, Desmond RA, Gordetsky JB, Azrad M, Frugé AD, Yang ES, Norian LA, Grizzle WE.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):293-294. doi: 10.1038/s41391-018-0038-9. Epub 2018 Apr 24. No abstract available.

24.

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 May;17(5):921-930. doi: 10.1158/1535-7163.MCT-17-0302. Epub 2018 Mar 28.

25.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.

26.

Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.

Georgiev IS, Joyce MG, Chen RE, Leung K, McKee K, Druz A, Van Galen JG, Kanekiyo M, Tsybovsky Y, Yang ES, Yang Y, Acharya P, Pancera M, Thomas PV, Wanninger T, Yassine HM, Baxa U, Doria-Rose NA, Cheng C, Graham BS, Mascola JR, Kwong PD.

ACS Infect Dis. 2018 May 11;4(5):788-796. doi: 10.1021/acsinfecdis.7b00192. Epub 2018 Mar 6.

PMID:
29451984
27.

Functional interrogation and mining of natively paired human VH:VL antibody repertoires.

Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G.

Nat Biotechnol. 2018 Feb;36(2):152-155. doi: 10.1038/nbt.4052. Epub 2018 Jan 8.

28.

ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.

Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL.

J Biol Chem. 2018 Jan 19;293(3):984-994. doi: 10.1074/jbc.M117.808584. Epub 2017 Nov 30.

29.

Degradation kinetics study of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) by a validated stability-indicating RP-HPLC method.

Kim KS, Yang ES, Kim DS, Kim DW, Yong CS, Kim JO, Jin SG, Choi HG.

J Pharm Biomed Anal. 2018 Feb 5;149:374-380. doi: 10.1016/j.jpba.2017.11.005. Epub 2017 Nov 13.

PMID:
29145099
30.

JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.

Garcia PL, Miller AL, Gamblin TL, Council LN, Christein JD, Arnoletti JP, Heslin MJ, Reddy S, Richardson JH, Cui X, van Waardenburg RCAM, Bradner JE, Yang ES, Yoon KJ.

Mol Cancer Ther. 2018 Jan;17(1):107-118. doi: 10.1158/1535-7163.MCT-16-0922. Epub 2017 Nov 15.

31.

DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.

Dulaney CR, Rais-Bahrami S, Manna DD, Gordetsky JB, Nix JW, Yang ES.

Oncotarget. 2017 Jul 10;8(40):68038-68046. doi: 10.18632/oncotarget.19145. eCollection 2017 Sep 15.

32.

Effect of inorganic mesoporous carriers on 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol-loaded solid self-emulsifying drug delivery system: Physicochemical characterization and bioavailability in rats.

Kim DS, Yang ES, Yong CS, Youn YS, Oh KT, Li DX, Kim JO, Jin SG, Choi HG.

Colloids Surf B Biointerfaces. 2017 Dec 1;160:331-336. doi: 10.1016/j.colsurfb.2017.09.041. Epub 2017 Sep 19.

PMID:
28957774
33.

The Impact of DNA Repair Pathways in Cancer Biology and Therapy.

Nikolaev A, Yang ES.

Cancers (Basel). 2017 Sep 19;9(9). pii: E126. doi: 10.3390/cancers9090126.

34.

Implementation and utilization of the molecular tumor board to guide precision medicine.

Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.

Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22. Review.

35.

Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.

Demark-Wahnefried W, Rais-Bahrami S, Desmond RA, Gordetsky JB, Hunter GR, Yang ES, Azrad M, Frugé AD, Tsuruta Y, Norian LA, Segal R, Grizzle WE.

Br J Cancer. 2017 Oct 24;117(9):1303-1313. doi: 10.1038/bjc.2017.303. Epub 2017 Sep 7.

36.

Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer.

McDonald AM, Fiveash JB, Kirkland RS, Cardan RA, Jacob R, Kim RY, Dobelbower MC, Yang ES.

Urol Oncol. 2017 Nov;35(11):663.e15-663.e21. doi: 10.1016/j.urolonc.2017.07.012. Epub 2017 Aug 7.

PMID:
28797587
37.

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Kwong PD, Koup RA, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB.

Sci Immunol. 2017 Jul 14;2(13). pii: eaan2676. doi: 10.1126/sciimmunol.aan2676.

PMID:
28783708
38.

A step towards predicting checkpoint inhibitor response in kidney cancer.

Maia MC, Yang ES, Agarwal N, Pal SK.

Lancet Oncol. 2017 Aug;18(8):982-983. doi: 10.1016/S1470-2045(17)30533-8. Epub 2017 Jul 26. No abstract available.

39.

Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets.

Necchi A, Eigl BJ, Yang ES, Bae S, Chandrashekar D, Chen D, Naik G, Mehta A, Giannatempo P, Colecchia M, Gordetsky J, Wei S, Cooper T, Varambally S, Sonpavde G.

Eur Urol Focus. 2018 Sep;4(5):733-736. doi: 10.1016/j.euf.2016.08.001. Epub 2016 Aug 27.

40.

A novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for improved stability and oral bioavailability of an oily drug, 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol.

Kim KS, Yang ES, Kim DS, Kim DW, Yoo HH, Yong CS, Youn YS, Oh KT, Jee JP, Kim JO, Jin SG, Choi HG.

Drug Deliv. 2017 Nov;24(1):1018-1025. doi: 10.1080/10717544.2017.1344335.

PMID:
28675315
41.

Occupational Risk of Latent Tuberculosis Infection in Health Workers of 14 Military Hospitals.

Yoon CG, Oh SY, Lee JB, Kim MH, Seo Y, Yang J, Bae KJ, Hong S, Yang ES, Kim HJ.

J Korean Med Sci. 2017 Aug;32(8):1251-1257. doi: 10.3346/jkms.2017.32.8.1251.

42.

MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines.

Rohrbach TD, Jones RB, Hicks PH, Weaver AN, Cooper TS, Eustace NJ, Yang ES, Jarboe JS, Anderson JC, Willey CD.

Oncol Lett. 2017 Mar;13(3):1216-1222. doi: 10.3892/ol.2016.5550. Epub 2016 Dec 29.

43.

Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets.

Yang ES, Willey CD, Mehta A, Crowley MR, Crossman DK, Chen D, Anderson JC, Naik G, Della Manna DL, Cooper TS, Sonpavde G.

Oncotarget. 2017 Mar 28;8(13):21710-21718. doi: 10.18632/oncotarget.15558.

44.

Cyclin C regulates adipogenesis by stimulating transcriptional activity of CCAAT/enhancer-binding protein α.

Song Z, Xiaoli AM, Zhang Q, Zhang Y, Yang EST, Wang S, Chang R, Zhang ZD, Yang G, Strich R, Pessin JE, Yang F.

J Biol Chem. 2017 May 26;292(21):8918-8932. doi: 10.1074/jbc.M117.776229. Epub 2017 Mar 28.

45.

Potential biomarkers for radiosensitivity in head and neck cancers.

Pardo-Reoyo S, Roig-Lopez JL, Yang ES.

Ann Transl Med. 2016 Dec;4(24):524. doi: 10.21037/atm.2016.12.45.

46.

Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.

Zeng L, Beggs RR, Cooper TS, Weaver AN, Yang ES.

Mol Cancer Ther. 2017 Apr;16(4):591-600. doi: 10.1158/1535-7163.MCT-16-0352. Epub 2017 Jan 30.

47.

Poly(ADP-ribose) polymerase activity and inhibition in cancer.

Dulaney C, Marcrom S, Stanley J, Yang ES.

Semin Cell Dev Biol. 2017 Mar;63:144-153. doi: 10.1016/j.semcdb.2017.01.007. Epub 2017 Jan 10. Review.

PMID:
28087320
48.

Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors.

Wielgos ME, Rajbhandari R, Cooper TS, Wei S, Nozell S, Yang ES.

Mol Cancer Res. 2017 Mar;15(3):340-347. doi: 10.1158/1541-7786.MCR-16-0287-T. Epub 2016 Dec 28.

49.

MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2.

Kang DW, Yang ES, Noh YN, Hwang WC, Jo SY, Suh YA, Park WS, Choi KY, Min DS.

J Pathol. 2017 Apr;241(5):614-625. doi: 10.1002/path.4866. Epub 2017 Feb 17.

PMID:
28008607
50.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

Supplemental Content

Support Center